Pages that link to "Q45163889"

The following pages link to Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen (Q45163889):

Displaying 33 items.

• Interplay of estrogen receptors and FOXA factors in the liver cancer (Q28081337) (← links)
• Management of hepatocellular carcinoma (Q29616230) (← links)
• Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? (Q30234736) (← links)
• Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis (Q34194760) (← links)
• Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription (Q34546701) (← links)
• The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis (Q35144521) (← links)
• Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma (Q35621256) (← links)
• Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives (Q35742116) (← links)
• Haematogenous abdominal wall metastasis of differentiated, alpha-fetoprotein-negative hepatocellular carcinoma after previous antiandrogen therapy within a site of lipoma manifestation since childhood (Q36127730) (← links)
• Hepatocellular carcinoma: natural history, current management, and emerging tools (Q36171275) (← links)
• Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. (Q36476765) (← links)
• New aspects of diagnosis and therapy of hepatocellular carcinoma. (Q36519032) (← links)
• Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study (Q36611050) (← links)
• Characteristics and quality of randomized controlled trials in the treatment of hepatocellular carcinoma (Q36753380) (← links)
• Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis (Q36904589) (← links)
• The androgen receptor as an emerging target in hepatocellular carcinoma (Q37031766) (← links)
• Is human hepatocellular carcinoma a hormone-responsive tumor? (Q37113547) (← links)
• The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals (Q37363464) (← links)
• Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. (Q37365527) (← links)
• Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells (Q37564767) (← links)
• Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver (Q38123063) (← links)
• Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma (Q38802507) (← links)
• Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. (Q39020826) (← links)
• Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion (Q39310796) (← links)
• Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin (Q39985777) (← links)
• Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. (Q40700985) (← links)
• Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future (Q42343451) (← links)
• Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals (Q47161820) (← links)
• Significance and Mechanism of Androgen Receptor (AR) Overexpression and AR-mTOR Crosstalk in Hepatocellular Carcinoma (Q47315253) (← links)
• Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? (Q64068788) (← links)
• [Palliative treatment of hepatocellular carcinoma] (Q80052042) (← links)
• Androgen Receptor (AR)-TLR4 Crosstalk Mediates Gender Disparities in Hepatocellular Carcinoma Incidence and Progression (Q92758027) (← links)
• Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma (Q97419057) (← links)